With multiple PSMA PET tracers available, Jaideep S. Sohi, MD, shares insights about the benefits of the various options and his real-world experience with their use in practice.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.